In silico modelling of thymoquinone disruption of PCSK9-LDLR binding for cholesterol regulation
No Thumbnail Available
Date
2026-05-02
Journal Title
Journal ISSN
Volume Title
Publisher
Institute Of Chemistry Ceylon
Abstract
Cardiovascular disease remains a leading cause
of global mortality, with hypercholesterolemia
identified as a major modifiable risk factor. Proprotein
convertase subtilisin/kexin type 9 (PCSK9) regulates
cholesterol by binding to the EGF-A domain of the
low-density lipoprotein receptor (LDLR), promoting
its degradation and thereby reducing LDL-cholesterol
clearance.
Description
Abstract No: 2025_425
Page No 88
Keywords
Thymoquinone, PCSK9, LDLR, molecular docking, molecular dynamics